Being equipped for clinical PET

Affiliations

M J O'Doherty et al. Lancet. 2000.

. 2000 Nov 18;356(9243):1701-3.

doi: 10.1016/s0140-6736(00)03200-1.

¹ Department of Radiological Sciences, Guys, Kings, and St Thomas' School of Medicine, and Clinical PET Centre, St Thomas' Hospital, London, UK.

No abstract available

Comment in

Trends in use of positron emission tomography.
Tashiro M, Kubota K, Itoh M, Moser E. Tashiro M, et al. Lancet. 2001 Mar 17;357(9259):886. doi: 10.1016/S0140-6736(05)71820-1. Lancet. 2001. PMID: 11265983 No abstract available.

The need for Health Technology Assessments of PET.
Van Tinteren H, Hoekstra OS, Boers M. Van Tinteren H, et al. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1438-9; author reply 1439. doi: 10.1007/s00259-003-1294-y. Epub 2003 Jul 31. Eur J Nucl Med Mol Imaging. 2003. PMID: 12898206 No abstract available.
Are health technology assessments a reliable tool in th analysis of the clinical value of PET in oncology? Who audits the auditors?
Højgaard L. Højgaard L. Eur J Nucl Med Mol Imaging. 2003 May;30(5):637-41. doi: 10.1007/s00259-003-1203-4. Eur J Nucl Med Mol Imaging. 2003. PMID: 12838956 No abstract available.
Clinical PET in oncology.
Biersack HJ, Bender H, Ruhlmann J, Oehr P, Guhlke S, Grünwald F. Biersack HJ, et al. Rev Esp Med Nucl. 2000 Jun;19(3):219-24. Rev Esp Med Nucl. 2000. PMID: 11062087 No abstract available.
[Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Comans EF, Hoekstra OS, Hoekman K, van der Hoeven JJ, Golding RP, Teule GJ. Comans EF, et al. Ned Tijdschr Geneeskd. 2000 Aug 5;144(32):1520-8. Ned Tijdschr Geneeskd. 2000. PMID: 10949634 Review. Dutch.
Positron emission tomography (PET) in the evaluation of patients with cancer.
Godwin HA Jr, Zuger JH. Godwin HA Jr, et al. Trans Am Clin Climatol Assoc. 1999;110:181-94. Trans Am Clin Climatol Assoc. 1999. PMID: 10344016 Free PMC article. Review. No abstract available.